Klow

Studied for combined tissue-repair and inflammation-related endpoints, bringing together repair-associated peptides and an α-MSH-derived anti-inflammatory tripeptide. The evidence base is the preclinical literature of the individual components.

Combines matrix remodelling and cell migration (GHK-Cu, TB-500), cytoprotection and angiogenesis (BPC-157), and anti-inflammatory melanocortin signalling (KPV).

Each component is a research compound, not an approved medicine; BPC-157, TB-500, and KPV are in the FDA’s July 2026 advisory-committee peptide review and GHK-Cu in the February 2027 group (U.S.). This does not change the blend’s research-use status in Canada - not for human consumption.

A single vial containing an 80 mg blend (GHK-Cu 50 mg, TB-500 10 mg, BPC-157 10 mg, KPV 10 mg) as a lyophilised powder.

• As a blend, the references below are the key papers for the individual components. - Pickart L, Margolina A. (2018). GHK-Cu peptide review. Int. J. Molecular Sciences, 19(7):1987.
• Goldstein AL, et al. (2005). Thymosin β4… repair of injured tissues. Trends in Molecular Medicine, 11(9):421-429. - TB-500 component
• Dalmasso G, et al. (2008). PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology, 134(1):166-178. - KPV component